Genmab and AbbVie provided clarification on the primary endpoints from the Phase 3 EPCORE DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared… read more.
Shield Therapeutics announced the publication of the positive efficacy, tolerability and palatability results from the ferric maltol pediatric FORTIS clinical trial, comparing the safety and efficacy of ferric… read more.
For people with lymphoma, getting the right diagnosis can be a race against time. Symptoms such as swollen lymph nodes, fever, weight loss and fatigue can be signs… read more.
Bristol Myers Squibb announced that the FDA has approved ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple… read more.
10 August 2026 – Kura Oncology, Inc. announced the publication of a manuscript in Blood, the flagship journal of the American Society of Hematology, detailing the discovery and… read more.
Genmab A/S announced that the European Commission (EC) granted marketing authorization for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R2) for the treatment of adult… read more.
Nuvectis Pharma announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from the National Medicinal Products Administration of China (NMPA) for the treatment… read more.
A new report in The Lancet Haematology, led by Cleveland Clinic hematologist Bethany Samuelson Bannow, M.D., outlines practical strategies to improve diagnosis, care and outcomes globally for women and girls with hematological conditions,… read more.
Pfizer Inc. announced that the FDA has approved an expanded indication for Hympavzi (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and… read more.
AbbVie announced that the FDA has approved Decnupaz (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options…. read more.
AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple… read more.
The MHRA confirmed that it granted a UK marketing authorisation to Wayrilz (rilzabrutinib) for adults with immune thrombocytopenia (ITP) whose previous treatments have not worked sufficiently. The approval… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
